Physician profile
Erin E Bishop
NPI 1598453458
$633.49
in general payments reported to CMS, 2019-2025
11 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $167 · 2024: $326 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $151.27 | 2023-2025 | Phexxi, Solosec, Phexx |
| Sumitomo Pharma America, INC. | $107.80 | 2023-2024 | Myfembree |
| Astellas Pharma US INC | $99.99 | 2024 | |
| Coopersurgical, INC. | $65.73 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Baxter Healthcare | $49.44 | 2025 | Perclot |
| Abbvie INC. | $44.45 | 2023 | |
| Pfizer INC. | $30.01 | 2023-2024 | |
| Aspira Women'S Health INC | $25.50 | 2024 | Ova1 |
| Exeltis, USA INC. | $23.97 | 2025 | Slynd |
| Merck Sharp & Dohme LLC | $17.73 | 2024 | Gardasil, Gardasil 9 |
| Arjo INC. | $17.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.